AIM ImmunoTech (AIM) Competitors $0.20 +0.01 (+3.94%) (As of 12/24/2024 04:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends AIM vs. BRNS, OMGA, VIRI, CVM, VTVT, ICCC, GANX, ALRN, CDIO, and ACHLShould you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Barinthus Biotherapeutics (BRNS), Omega Therapeutics (OMGA), Virios Therapeutics (VIRI), CEL-SCI (CVM), vTv Therapeutics (VTVT), ImmuCell (ICCC), Gain Therapeutics (GANX), Aileron Therapeutics (ALRN), Cardio Diagnostics (CDIO), and Achilles Therapeutics (ACHL). These companies are all part of the "pharmaceutical products" industry. AIM ImmunoTech vs. Barinthus Biotherapeutics Omega Therapeutics Virios Therapeutics CEL-SCI vTv Therapeutics ImmuCell Gain Therapeutics Aileron Therapeutics Cardio Diagnostics Achilles Therapeutics Barinthus Biotherapeutics (NASDAQ:BRNS) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment. Does the MarketBeat Community prefer BRNS or AIM? AIM ImmunoTech received 45 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 83.10% of users gave AIM ImmunoTech an outperform vote. CompanyUnderperformOutperformBarinthus BiotherapeuticsOutperform Votes14100.00% Underperform VotesNo VotesAIM ImmunoTechOutperform Votes5983.10% Underperform Votes1216.90% Which has higher earnings & valuation, BRNS or AIM? AIM ImmunoTech has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBarinthus Biotherapeutics$14.97M2.98-$73.35M-$1.49-0.74AIM ImmunoTech$190K65.46-$28.96M-$0.47-0.41 Which has more risk & volatility, BRNS or AIM? Barinthus Biotherapeutics has a beta of -0.73, indicating that its stock price is 173% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.36, indicating that its stock price is 136% less volatile than the S&P 500. Does the media prefer BRNS or AIM? In the previous week, AIM ImmunoTech had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 2 mentions for AIM ImmunoTech and 0 mentions for Barinthus Biotherapeutics. AIM ImmunoTech's average media sentiment score of 0.12 beat Barinthus Biotherapeutics' score of 0.00 indicating that AIM ImmunoTech is being referred to more favorably in the news media. Company Overall Sentiment Barinthus Biotherapeutics Neutral AIM ImmunoTech Neutral Do insiders & institutionals believe in BRNS or AIM? 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are held by institutional investors. 8.0% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is BRNS or AIM more profitable? Barinthus Biotherapeutics has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Barinthus Biotherapeutics' return on equity of -34.26% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets Barinthus BiotherapeuticsN/A -34.26% -29.30% AIM ImmunoTech -12,594.21%-421.73%-147.54% Do analysts prefer BRNS or AIM? Barinthus Biotherapeutics presently has a consensus target price of $5.83, suggesting a potential upside of 425.53%. AIM ImmunoTech has a consensus target price of $2.75, suggesting a potential upside of 1,310.26%. Given AIM ImmunoTech's higher probable upside, analysts clearly believe AIM ImmunoTech is more favorable than Barinthus Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAIM ImmunoTech beats Barinthus Biotherapeutics on 9 of the 17 factors compared between the two stocks. Ad Insiders ExposedMysterious drone activity triggers massive 1,366% surgeIf mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%.👉 Click here now to see how this signal works. Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIM vs. The Competition Export to ExcelMetricAIM ImmunoTechBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$12.44M$2.96B$5.22B$19.36BDividend YieldN/A1.91%5.12%3.65%P/E Ratio-0.4145.6887.5441.41Price / Sales65.46417.621,166.5918.16Price / CashN/A174.7643.2321.28Price / Book0.983.924.835.36Net Income-$28.96M-$42.00M$120.46M$989.88M7 Day Performance-0.51%3.88%2.85%1.63%1 Month Performance-8.45%-0.22%19.70%-4.78%1 Year Performance-59.79%18.86%30.57%12.48% AIM ImmunoTech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMAIM ImmunoTech2.4388 of 5 stars$0.20+3.9%$2.75+1,310.3%-59.8%$12.44M$190,000.00-0.4120BRNSBarinthus Biotherapeutics1.5795 of 5 stars$1.18+6.3%$5.83+394.4%-66.5%$47.47M$14.97M-0.79107Gap UpOMGAOmega Therapeutics2.0776 of 5 stars$0.82-2.5%$9.20+1,028.0%-66.3%$45.16M$8.10M-0.61120VIRIVirios TherapeuticsN/A$2.34+0.9%$3.00+28.2%+355.7%$45.06MN/A-8.675Gap UpCVMCEL-SCIN/A$0.70-3.8%N/A-74.5%$44.80MN/A-1.2143News CoverageVTVTvTv Therapeutics2.1735 of 5 stars$14.00-6.4%$35.00+150.0%+54.3%$44.66M$1M-3.099Gap DownICCCImmuCellN/A$4.87+6.3%N/A-1.5%$43.40M$23.84M-9.7475GANXGain Therapeutics3.4505 of 5 stars$1.57+0.6%$7.25+361.8%-35.6%$41.64M$50,000.00-1.4320Analyst ForecastNews CoverageALRNAileron Therapeutics3.7601 of 5 stars$1.89+8.0%$19.00+905.3%-31.1%$40.95MN/A-0.619Positive NewsHigh Trading VolumeCDIOCardio Diagnostics2.5524 of 5 stars$1.01+3.7%$2.00+98.0%-55.5%$40.84M$20,000.000.007ACHLAchilles Therapeutics3.2319 of 5 stars$0.98+0.1%$4.00+307.1%+39.0%$40.38MN/A-0.60250News Coverage Related Companies and Tools Related Companies BRNS Alternatives OMGA Alternatives VIRI Alternatives CVM Alternatives VTVT Alternatives ICCC Alternatives GANX Alternatives ALRN Alternatives CDIO Alternatives ACHL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:AIM) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AIM Stock Alerts